Multi‐Domain Cognitive Assessment in a Scopolamine‐Induced Mouse Model: Toward a Translational Framework
Guardado en:
| Publicado en: | Alzheimer's & Dementia vol. 21 (Dec 1, 2025) |
|---|---|
| Autor principal: | |
| Otros Autores: | , , , , , , |
| Publicado: |
John Wiley & Sons, Inc.
|
| Materias: | |
| Acceso en línea: | Citation/Abstract Full Text - PDF |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
MARC
| LEADER | 00000nab a2200000uu 4500 | ||
|---|---|---|---|
| 001 | 3286949791 | ||
| 003 | UK-CbPIL | ||
| 022 | |a 1552-5260 | ||
| 022 | |a 1552-5279 | ||
| 024 | 7 | |a 10.1002/alz70859_106326 |2 doi | |
| 035 | |a 3286949791 | ||
| 045 | 0 | |b d20251201 | |
| 100 | 1 | |a Kim, Jinhak |u Yonsei University College of Medicine, Seoul, Korea, Republic of (South) | |
| 245 | 1 | |a Multi‐Domain Cognitive Assessment in a Scopolamine‐Induced Mouse Model: Toward a Translational Framework | |
| 260 | |b John Wiley & Sons, Inc. |c Dec 1, 2025 | ||
| 513 | |a Journal Article | ||
| 520 | 3 | |a Background Dementia is a complex and heterogeneous condition, encompassing multiple subtypes and mixed pathologies that complicate translational research. Clinical assessments rely on neuropsychiatric evaluations to measure cognitive domains such as memory, attention, visuospatial function, executive function, and language. However, replicating these aspects in animal models remains a challenge. Implementing multi‐domain cognitive assessments in animal models is crucial for capturing the diverse cognitive impairments associated with dementia. Method Male C57BL/6 mice were administered scopolamine to induce cognitive impairments, followed by treatment with donepezil. Cognitive functions were assessed using a touchscreen‐based operant system through the following tasks: Visual Discrimination (VD), 5‐Choice Serial Reaction Time Task (5‐CSRTT), Fixed/Progressive Ratio (FR/PR), and Paired Associate Learning (PAL). Result In the VD task, scopolamine significantly reduced accuracy, confirming cognitive impairment, while donepezil reversed this effect, demonstrating the model’s sensitivity to treatment. In 5‐CSRTT, donepezil at 3 mg/kg effectively reversed scopolamine‐induced deficits, whereas 1.5 mg/kg was insufficient, indicating a dose‐dependent effect. In FR/PR, scopolamine increased the breakpoint, suggesting altered motivation, and donepezil did not reverse this effect, highlighting potential model limitations in assessing motivation‐related impairments. In PAL, scopolamine (1 mg/kg) reduced accuracy, confirming cognitive impairment in associative learning, but this effect was not reversed by donepezil. Conclusion The scopolamine‐induced cognitive impairment model demonstrated domain‐specific deficits with task‐ and dose‐dependent treatment responses. These findings emphasize the need for optimization and task refinement to enhance model reliability. Structuring these tasks into a comprehensive multi‐domain battery could provide a robust preclinical platform for evaluating potential therapeutics and advancing our understanding of dementia’s cognitive complexities. | |
| 653 | |a Cognitive functioning | ||
| 653 | |a Reliability | ||
| 653 | |a Dementia | ||
| 653 | |a Models | ||
| 653 | |a Animals | ||
| 653 | |a Clinical research | ||
| 653 | |a Cognition | ||
| 653 | |a Psychiatry | ||
| 653 | |a Cognitive ability | ||
| 653 | |a Associative learning | ||
| 653 | |a Reaction time | ||
| 653 | |a Visual discrimination | ||
| 653 | |a Motivation | ||
| 653 | |a Cognitive impairment | ||
| 653 | |a Paired associate learning | ||
| 653 | |a Discrimination | ||
| 653 | |a Public relations | ||
| 653 | |a Induced | ||
| 653 | |a Executive function | ||
| 653 | |a Optimization | ||
| 653 | |a Subtypes | ||
| 653 | |a Evaluation | ||
| 653 | |a Visual memory | ||
| 653 | |a Accuracy | ||
| 653 | |a Donepezil | ||
| 653 | |a Clinical assessment | ||
| 653 | |a Spatial memory | ||
| 653 | |a Visual-Spatial ability | ||
| 700 | 1 | |a Kim, Junho |u Yonsei University College of Medicine, Seoul, Korea, Republic of (South) | |
| 700 | 1 | |a Yang, Euimo |u Yonsei University College of Medicine, Seoul, Korea, Republic of (South) | |
| 700 | 1 | |a Lee, Jeong Yoon |u Yonsei University College of Medicine, Seoul, Korea, Republic of (South) | |
| 700 | 1 | |a Jeong, Ha Jin |u Yonsei University College of Medicine, Seoul, Korea, Republic of (South) | |
| 700 | 1 | |a Kim, Hyunjeong |u Yonsei University College of Medicine, Seoul, Korea, Republic of (South) | |
| 700 | 1 | |a Kim, Keun You |u Yonsei University College of Medicine, Seoul, Korea, Republic of (South) | |
| 700 | 1 | |a Kim, Eosu |u Yonsei University College of Medicine, Seoul, Korea, Republic of (South) | |
| 773 | 0 | |t Alzheimer's & Dementia |g vol. 21 (Dec 1, 2025) | |
| 786 | 0 | |d ProQuest |t Consumer Health Database | |
| 856 | 4 | 1 | |3 Citation/Abstract |u https://www.proquest.com/docview/3286949791/abstract/embedded/7BTGNMKEMPT1V9Z2?source=fedsrch |
| 856 | 4 | 0 | |3 Full Text - PDF |u https://www.proquest.com/docview/3286949791/fulltextPDF/embedded/7BTGNMKEMPT1V9Z2?source=fedsrch |